Mouse monoclonal antibody raised against native GP5.
Native purified GP5 from human platelets.
The monoclonal antibody is directed against the 82 kD GP V antigen, which is expressed on human platelets. The monoclonal antibody reacts with human platelet. It has been shown that the glycoproteins GP V and GPIb-GP IX form a noncovalent complex in the platelet membrane. The monoclonal antibody does not react with lymphocytes, granulocytes, monocytes and erythrocytes. Antigen is expressed on human platelets and megakaryocytes. The antigen is absent or present in very low levels on platelets of patients with the Bernard-Soulier syndrome.
The optimal working dilution should be determined by the end user.
In 20 mM Tris, 150 mM NaCl, pH 8.0 (10 mg BSA, 0.001% thimerosal)
Store at 4°C.
This product contains thimerosal: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Human platelet glycoprotein V (GP5) is a part of the Ib-V-IX system of surface glycoproteins that constitute the receptor for von Willebrand factor (VWF; MIM 193400) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis. The main portion of the receptor is a heterodimer composed of 2 polypeptide chains, an alpha chain (GP1BA; MIM 606672) and a beta chain (GP1BB; MIM 138720), that are linked by disulfide bonds. The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX (GP9; MIM 173515) and GP5. Mutations in GP1BA, GP1BB, and GP9 have been shown to cause Bernard-Soulier syndrome (MIM 231200), a bleeding disorder.[supplied by OMIM